Squarepoint’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-415,706
| Closed | -$8.91M | – | 4517 |
|
|
2026
Q1 | $8.91M | Buy |
415,706
+315,094
| +313% | +$4.44M | 0.01% | 1135 |
|
|
2025
Q4 | $938K | Buy |
+100,612
| New | +$841K | ﹤0.01% | 2671 |
|
|
2025
Q2 | – | Sell |
-41,326
| Closed | -$328K | – | 4595 |
|
|
2025
Q1 | $328K | Buy |
41,326
+11,297
| +38% | +$122K | ﹤0.01% | 3673 |
|
|
2024
Q4 | $380K | Buy |
+30,029
| New | +$418K | ﹤0.01% | 3971 |
|
|
2024
Q3 | – | Sell |
-186,484
| Closed | -$2.57M | – | 4209 |
|
|
2024
Q2 | $2.57M | Buy |
+186,484
| New | +$2.73M | ﹤0.01% | 1856 |
|
|
2024
Q1 | – | Sell |
-15,927
| Closed | -$233K | – | 4136 |
|
|
2023
Q4 | $233K | Sell |
15,927
-30,917
| -66% | -$375K | ﹤0.01% | 3504 |
|
|
2023
Q3 | $575K | Sell |
46,844
-114,942
| -71% | -$1.5M | ﹤0.01% | 2686 |
|
|
2023
Q2 | $1.93M | Sell |
161,786
-62,191
| -28% | -$812K | 0.01% | 1676 |
|
|
2023
Q1 | $2.99M | Buy |
223,977
+193,161
| +627% | +$3.77M | 0.01% | 1157 |
|
|
2022
Q4 | $663K | Buy |
+30,816
| New | +$632K | ﹤0.01% | 2104 |
|
|
2021
Q3 | – | Sell |
-18,927
| Closed | -$431K | – | 3003 |
|
|
2021
Q2 | $431K | Buy |
+18,927
| New | +$395K | ﹤0.01% | 2252 |
|
Other funds holding DAWN
Squarepoint's DAWN Position: Q2 2026 in Review
Squarepoint sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 415,706 shares — an estimated $8.91M sold.
Squarepoint first reported a position in DAWN in Q2 2021 and held it in 11 quarters. The position peaked at $8.91M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Squarepoint reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Squarepoint sold 415,706 Day One Biopharmaceuticals shares in Q2 2026, an estimated $8.91M.
- Squarepoint first reported a position in Day One Biopharmaceuticals in Q2 2021 and held it in 11 quarters.
- Squarepoint's Day One Biopharmaceuticals position peaked at $8.91M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.